Get report status and results
Poll the status of a report created via POST /api/v2/sessions/reports.
Status transitions
- processing — Elicit is actively searching, screening, and extracting data. You can watch progress in real time at the url.
- pausedForInsufficientQuota — The account exceeded its usage limit mid-run. The report stays paused until resumed via the links.resume URL (or the Elicit web interface) once the limit is resolved.
- completed — The report is finished. The result field contains the report content.
- failed — Something went wrong. The error field contains details.
- unknown — Status is not tracked for this report (legacy or user-created reports).
Polling recommendation
Poll every 30–60 seconds. Reports typically complete in 5–15 minutes depending on the number of papers.
Including the full report body
By default, the reportBody and abstract fields are omitted to keep polling responses lightweight. To include them, add ?include=reportBody to the request.
Example
# Poll for status
curl https://elicit.com/api/v2/sessions/reports/{sessionId} \
-H "Authorization: Bearer elk_live_your_key_here"
# Fetch with full report body
curl "https://elicit.com/api/v2/sessions/reports/{sessionId}?include=reportBody" \
-H "Authorization: Bearer elk_live_your_key_here"
Path parameters
The session ID (UUID) returned by the create endpoints and GET /sessions
The session ID (UUID) returned by the create endpoints and GET /sessions
Query parameters
Set to 'reportBody' to include the full report markdown and abstract in the response
Set to 'reportBody' to include the full report markdown and abstract in the response
Response
Report status and results (if completed).
Example response
{
"sessionId": "5ad08bfb-cbe0-4911-a8c3-309760d33029",
"url": "https://elicit.com/review/5ad08bfb-cbe0-4911-a8c3-309760d33029",
"result": {
"title": "GLP-1 Receptor Agonists and Cardiovascular Outcomes: A Systematic Review",
"summary": "This review analyzed 42 studies examining the cardiovascular effects of GLP-1 receptor agonists. The evidence suggests significant reductions in major adverse cardiovascular events (MACE), with semaglutide showing the strongest effect (HR 0.74, 95% CI 0.58-0.95)...",
"reportBody": "# Introduction\n\nGLP-1 receptor agonists have emerged as...",
"abstract": "This systematic review examines the cardiovascular effects of..."
},
"pdfUrl": "https://s3.amazonaws.com/...",
"docxUrl": "https://s3.amazonaws.com/...",
"txtUrl": "https://s3.amazonaws.com/...",
"bibUrl": "https://s3.amazonaws.com/...",
"risUrl": "https://s3.amazonaws.com/...",
"links": {
"self": "https://elicit.com/api/v2/sessions/reports/5ad08bfb-cbe0-4911-a8c3-309760d33029",
"resume": "https://elicit.com/api/v2/sessions/5ad08bfb-cbe0-4911-a8c3-309760d33029/resume"
}
}Changes
No recorded changes to this endpoint across all 1 revision of this API.